Effects of combined SGLT2 inhibitor and DPP-4 inhibitor therapy on advanced glycation end products
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000049408
- Lead Sponsor
- Akishima Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Not provided
Exclusion Criteria
eGFR: less than 45 mL/min/1.73 m2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Methylglyoxal-derived hydroimidazolone-1 level in serum
- Secondary Outcome Measures
Name Time Method Body weight, Hemoglobin A1c level, serum lipids, and liver function marker
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does combined SGLT2 and DPP-4 inhibitor therapy modulate AGE accumulation in type 2 diabetes patients?
What is the comparative efficacy of SGLT2/DPP-4 inhibitor combination versus standard-of-care in managing AGEs in type 2 diabetes?
Which biomarkers predict response to SGLT2/DPP-4 inhibitor combination therapy in reducing AGEs in type 2 diabetes?
What are the potential adverse events associated with combined SGLT2 and DPP-4 inhibitor therapy in type 2 diabetes management?
How does the SGLT2/DPP-4 inhibitor combination compare to other AGE-targeting therapies in type 2 diabetes treatment?